<ul>
<li><strong>预计回购约 5 亿美元——获得股东最大批准——计划于 2026 年 1 月 7 日完成</strong></li>
</ul>
<ul>
<li><strong>资本回购将通过合成股票回购进行——结合了快速直接的资本偿还给股东和增强每股收益的反向股票拆分</strong></li>
</ul>
<ul>
<li><strong>QIAGEN 提前兑现承诺，计划到 2028 年底至少回购 10 亿美元，并考虑在 2026 年及以后增加回购方式</strong></li>
</ul>
<p>荷兰芬洛 --（商业资讯）--QIAGEN N.V.（纽约证券交易所代码：QGEN；法兰克福主要标准：QIA）今天宣布了通过合成股票回购向股东回购约 5 亿美元的计划细节，该回购结合了直接向 QIAGEN 股东偿还资本和反向股票拆分。</p>
<p>QIAGEN 在 2025 年 11 月宣布了回购计划，此次回购是在 QIAGEN 自 2024 年初以来通过合成股票回购和在 2025 年 6 月实施首次年度股息支付向股东回购约 6.5 亿美元之后进行的。</p>
<p>随着 2026 年 1 月完成此次合成股票回购，QIAGEN 将提前兑现承诺，计划到 2028 年底至少向股东回购 10 亿美元，并考虑在 2026 年及以后采取额外措施以增加回购。</p>
<p>2025 年 6 月的年度股东大会上，股东几乎一致批准了实施 5 亿美元回购的决议。这种方法旨在比传统的公开市场回购计划更快、更有效地向股东返还现金。它还通过减少流通股数量来增强每股收益（EPS）。</p>
<p>预计从现有现金储备的偿还将导致已发行股份数量减少约 5%（基于当前股价）。</p>
<p>合成股票回购的条款如下：</p>
<ul>
<li>每 20 股已发行的 QIAGEN 股票将合并为 19 股 QIAGEN 股票，预计将从 2025 年 12 月 18 日的 2.177 亿股减少约 1090 万股。</li>
</ul>
<ul>
<li>在实施合并后，QIAGEN 将向记录在案的股东偿还每股 2.29 美元的资本（由于 QIAGEN 股票的面值以欧元计，资本减少和偿还的相关公证文件将以欧元计。然而，支付将以美元进行）。</li>
</ul>
<p>在纽约证券交易所和法兰克福证券交易所，拆分前股票的最后交易日计划为 2026 年 1 月 7 日（星期三）。</p>
<p>自 2026 年 1 月 8 日（星期四）起，合并后的 QIAGEN 股票（不包括资本偿还的权利）预计将在法兰克福证券交易所（QIA）和纽约证券交易所（QGEN）以公司的当前股票代码开始交易。</p>
<p>合并后的 QIAGEN 股票将具有以下新的证券标识符：</p>
<p>ISIN: NL0015002SN0</p>
<p>CUSIP: N72482 156</p>
<p>WKN: A41HBE</p>
<p><strong>结算机制的技术细节</strong></p>
<p>在美国持有 QIAGEN 股票的股东，其持股将根据上述合并比例自动合并，任何零碎股份将计划出售并将收益存入其账户，生效日期为 2026 年 1 月 7 日（星期三）东部时间下午 4:00（“生效日期” 及前 ISIN / CUSIP / WKN 的最后交易日）。</p>
<p>资本偿还计划通过存托信托公司在随后的几天内向股东的各自经纪账户进行。生效日期时未结算的市场交易计划由存托信托公司进行对账，并按照市场惯例结算。</p>
<p>对于在德国及其他欧洲国家直接或间接通过 Clearstream Banking AG 持有 QIAGEN 股票的股东，这些持股预计将在 2026 年 1 月 7 日（星期三）欧洲时间收盘时通过其银行、经纪人和保管人进行合并。预计这些股东的资本偿还也将在随后的几天内进行。任何零碎股份将被出售并存入其账户。</p>
<p>直接在 Equiniti（前身为美国股票转让和信托公司（“AST”））持有 QIAGEN 股票的股东，计划根据上述合并比例自动合并其持股，并在生效日期生效，通过 Equiniti 持有的登记进行处理，并将资本偿还存入公司已知的银行账户。</p>
<p>建议股东在有关反向股票拆分和资本偿还方面咨询其银行或经纪人。</p>
<p>建议股东咨询当地税务顾问以了解其税务状况。</p>
<p><strong>关于 QIAGEN</strong></p>
<p>QIAGEN N.V.是一家总部位于荷兰的控股公司，是全球领先的样本到洞察解决方案提供商，使客户能够从包含生命基本构件的生物样本中提取和分析分子信息。我们的样本技术从血液、组织和其他材料中分离和处理 DNA、RNA 和蛋白质。检测技术为这些生物分子准备分析，而生物信息学支持复杂数据的解释，以提供可操作的洞察。自动化解决方案将这些步骤整合到简化、成本效益高的工作流程中。QIAGEN 在生命科学（学术界、制药研发和工业应用如法医）和分子诊断（临床医疗）领域为全球超过 500,000 名客户提供服务。截至 2025 年 9 月 30 日，QIAGEN 在 35 个以上的地点雇佣了约 5,700 名员工。有关更多信息，请访问 https://www.qiagen.com。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿中的某些声明可能构成根据《1933 年美国证券法》第 27A 条和《1934 年美国证券交易法》第 21E 条的前瞻性声明。这些声明包括关于 QIAGEN 产品、开发时间表、市场和/或监管批准、财务和运营前景、增长战略、资本配置战略、合作关系和运营结果（如预期净销售额和调整后稀释每股收益）、首席执行官过渡计划、收购 Parse Biosciences 的时间及预期收益，以及合成股票回购的时间及预期收益，均基于当前的预期和假设。然而，这些声明涉及不确定性和风险。这些风险包括但不限于：在提供运营连续性和持续推进公司战略的同时，成功管理首席执行官过渡和继任者搜索的挑战；管理增长和国际运营的挑战（包括货币波动、关税、税法、监管流程和物流依赖的影响）；运营结果的变动以及为生命科学和临床医疗市场客户开发产品的商业化；与客户、供应商或战略合作伙伴关系的变化；竞争和快速的技术进步；证券市场的发展或变化以及 QIAGEN 股票的交易量和市场价格的波动，以及合成股票回购的成功实施；QIAGEN 成功完成、整合并实现收购 Parse Biosciences 的预期收益的能力，包括由于经济状况、客户预算和资金周期等因素导致的 QIAGEN 产品需求波动；获得和维持我们产品的监管批准；成功将 QIAGEN 的产品适应为综合解决方案并生产这些产品的困难；以及保护产品差异化以防止竞争对手的影响。市场对新产品的接受度、收购的整合、政府行为、全球或区域经济发展、自然灾害、政治或公共卫生危机以及其他 “不可抗力” 事件可能会带来额外的风险和不确定性。此外，重组计划和收购所预期的收益也没有保证会如预期那样实现。有关风险和不确定性的更完整讨论，请参阅我们最近的 20-F 表格年报和其他提交给或提供给美国证券交易委员会的报告中的 “风险因素” 部分。</p>
<p>来源：QIAGEN N.V.</p>
<p>类别：企业</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTgyMTcxNzJyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTgyMTcxNzJyMQ"/></p>
<p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251218217172/en/</p>
<p><strong>联系人 QIAGEN：</strong></p>
<p><strong>投资者关系</strong></p>
<p>电子邮件：ir@QIAGEN.com</p>
<p><strong>公共关系</strong></p>
<p>电子邮件：pr@QIAGEN.com</p>
<p>来源：QIAGEN N.V.</p>

快而精医药

<p>QIAGEN N.V. 宣布完成了一项约 5 亿美元的合成股票回购，计划于 2026 年 1 月 7 日进行。此次回购结合了对股东的直接资本返还和反向股票拆分，减少了 5% 的流通股。此举是 QIAGEN 承诺在 2028 年之前至少向股东返还 10 亿美元的一部分。股东在 2025 年 6 月批准了该计划。新的合并股份将于 2026 年 1 月 8 日开始交易</p>

<ul>
<li><strong>Return of approximately $500 million – maximum approved by shareholders – set to be completed on January 7, 2026</strong></li>
</ul>
<div class="lb-trans"><ul>
<li><strong>预计回购约 5 亿美元——获得股东最大批准——计划于 2026 年 1 月 7 日完成</strong></li>
</ul>
</div><ul>
<li><strong>Capital return to be conducted through synthetic share repurchase – combines a fast direct capital repayment to shareholders with a reverse stock split that enhances EPS</strong></li>
</ul>
<div class="lb-trans"><ul>
<li><strong>资本回购将通过合成股票回购进行——结合了快速直接的资本偿还给股东和增强每股收益的反向股票拆分</strong></li>
</ul>
</div><ul>
<li><strong>QIAGEN delivers well ahead of schedule on its commitment to return at least $1 billion through end-2028, considering additional ways to increase returns in 2026 and beyond</strong></li>
</ul>
<div class="lb-trans"><ul>
<li><strong>QIAGEN 提前兑现承诺，计划到 2028 年底至少回购 10 亿美元，并考虑在 2026 年及以后增加回购方式</strong></li>
</ul>
</div><p>VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced details for completion of plans to return approximately $500 million to shareholders through a synthetic share repurchase that combines a direct capital repayment to QIAGEN shareholders with a reverse stock split.</p>
<div class="lb-trans"><p>荷兰芬洛 --（商业资讯）--QIAGEN N.V.（纽约证券交易所代码：QGEN；法兰克福主要标准：QIA）今天宣布了通过合成股票回购向股东回购约 5 亿美元的计划细节，该回购结合了直接向 QIAGEN 股东偿还资本和反向股票拆分。</p>
</div><p>QIAGEN announced in November 2025 plans for the repurchase, which comes after QIAGEN has returned about $650 million to shareholders since the start of 2024 through a synthetic share repurchase and the implementation of the first annual dividend payment in June 2025.</p>
<div class="lb-trans"><p>QIAGEN 在 2025 年 11 月宣布了回购计划，此次回购是在 QIAGEN 自 2024 年初以来通过合成股票回购和在 2025 年 6 月实施首次年度股息支付向股东回购约 6.5 亿美元之后进行的。</p>
</div><p>With the completion of this synthetic share repurchase in January 2026, QIAGEN will have delivered well ahead of schedule on its commitment to return at least $1 billion to shareholders by the end of 2028, and is considering additional measures to increase returns in 2026 and beyond.</p>
<div class="lb-trans"><p>随着 2026 年 1 月完成此次合成股票回购，QIAGEN 将提前兑现承诺，计划到 2028 年底至少向股东回购 10 亿美元，并考虑在 2026 年及以后采取额外措施以增加回购。</p>
</div><p>Shareholders at the Annual General Meeting in June 2025 gave virtually unanimous approval for resolutions to implement the $500 million repurchase. This approach is designed to return cash to shareholders in a faster and more efficient way than through a traditional open-market repurchase program. It also enhances earnings per share (EPS) through the reduction in outstanding shares.</p>
<div class="lb-trans"><p>2025 年 6 月的年度股东大会上，股东几乎一致批准了实施 5 亿美元回购的决议。这种方法旨在比传统的公开市场回购计划更快、更有效地向股东返还现金。它还通过减少流通股数量来增强每股收益（EPS）。</p>
</div><p>The repayment from existing cash reserves is expected to lead to an approximately 5% reduction in the number of issued shares (based on current share price).</p>
<div class="lb-trans"><p>预计从现有现金储备的偿还将导致已发行股份数量减少约 5%（基于当前股价）。</p>
</div><p>The terms of the synthetic share repurchase are as follows:</p>
<div class="lb-trans"><p>合成股票回购的条款如下：</p>
</div><ul>
<li>Every 20 issued QIAGEN shares will be consolidated into 19 QIAGEN shares, leading to a reduction of approximately 10.9 million shares from the level of 217.7 million shares as of December 18, 2025.</li>
</ul>
<div class="lb-trans"><ul>
<li>每 20 股已发行的 QIAGEN 股票将合并为 19 股 QIAGEN 股票，预计将从 2025 年 12 月 18 日的 2.177 亿股减少约 1090 万股。</li>
</ul>
</div><ul>
<li>Following the implementation of the consolidation, QIAGEN will repay capital to shareholders of record $2.29 per pre-consolidation share. (As the par-value of QIAGEN shares is denominated in euros, the amount of the capital decrease and repayment in the respective notarial deeds will be denominated in euros. The payment, however, will be made in U.S. dollars.)</li>
</ul>
<div class="lb-trans"><ul>
<li>在实施合并后，QIAGEN 将向记录在案的股东偿还每股 2.29 美元的资本（由于 QIAGEN 股票的面值以欧元计，资本减少和偿还的相关公证文件将以欧元计。然而，支付将以美元进行）。</li>
</ul>
</div><p>The last day of trading of the pre-split shares on the New York Stock Exchange and the Frankfurt Stock Exchange is planned to be Wednesday, January 7, 2026.</p>
<div class="lb-trans"><p>在纽约证券交易所和法兰克福证券交易所，拆分前股票的最后交易日计划为 2026 年 1 月 7 日（星期三）。</p>
</div><p>Beginning on Thursday, January 8, 2026, the consolidated QIAGEN shares, excluding the entitlement to the capital repayment, are expected to begin trading on the Frankfurt Stock Exchange (QIA) and on the NYSE (QGEN) under the Company’s current ticker symbols.</p>
<div class="lb-trans"><p>自 2026 年 1 月 8 日（星期四）起，合并后的 QIAGEN 股票（不包括资本偿还的权利）预计将在法兰克福证券交易所（QIA）和纽约证券交易所（QGEN）以公司的当前股票代码开始交易。</p>
</div><p>The consolidated QIAGEN shares will carry the following new security identifiers:</p>
<div class="lb-trans"><p>合并后的 QIAGEN 股票将具有以下新的证券标识符：</p>
</div><p>ISIN: NL0015002SN0</p>
<div class="lb-trans"><p>ISIN: NL0015002SN0</p>
</div><p>CUSIP: N72482 156</p>
<div class="lb-trans"><p>CUSIP: N72482 156</p>
</div><p>WKN: A41HBE</p>
<div class="lb-trans"><p>WKN: A41HBE</p>
</div><p><strong>Technical details regarding settlement mechanics</strong></p>
<div class="lb-trans"><p><strong>结算机制的技术细节</strong></p>
</div><p>Shareholders holding their QIAGEN shares in brokerage accounts in the United States will have their holdings automatically consolidated in line with the consolidation ratio described above, whereby any fractional shares are planned to be sold and proceeds deposited in their account, effective as of close of business at 4:00 p.m. EST on Wednesday, January 7, 2026 (the “Effective Date” and the last trading day of the prior ISIN / CUSIP / WKN).</p>
<div class="lb-trans"><p>在美国持有 QIAGEN 股票的股东，其持股将根据上述合并比例自动合并，任何零碎股份将计划出售并将收益存入其账户，生效日期为 2026 年 1 月 7 日（星期三）东部时间下午 4:00（“生效日期” 及前 ISIN / CUSIP / WKN 的最后交易日）。</p>
</div><p>The capital repayment is planned to be made via Depository Trust Company to the respective brokerage accounts of the shareholders in the subsequent days. Unsettled market trades as of the Effective Date are planned to be reconciled by Depository Trust Company and settled in line with market practice.</p>
<div class="lb-trans"><p>资本偿还计划通过存托信托公司在随后的几天内向股东的各自经纪账户进行。生效日期时未结算的市场交易计划由存托信托公司进行对账，并按照市场惯例结算。</p>
</div><p>For shareholders who hold their QIAGEN shares in Germany and elsewhere in Europe directly or indirectly via Clearstream Banking AG, these holdings are expected to be consolidated through their banks, brokers and custodians as of close of business European time on Wednesday, January 7, 2026. The capital repayment for these shareholders is expected to also be made in the subsequent days. Any fractional shares will be sold and deposited in their account.</p>
<div class="lb-trans"><p>对于在德国及其他欧洲国家直接或间接通过 Clearstream Banking AG 持有 QIAGEN 股票的股东，这些持股预计将在 2026 年 1 月 7 日（星期三）欧洲时间收盘时通过其银行、经纪人和保管人进行合并。预计这些股东的资本偿还也将在随后的几天内进行。任何零碎股份将被出售并存入其账户。</p>
</div><p>Shareholders holding their QIAGEN shares in registered form directly at Equiniti (formerly American Stock Transfer and Trust Company (&#34;AST&#34;)) are planned to have their holdings automatically consolidated in line with the consolidation ratio described above by processing in the register held by Equiniti, effective as of the Effective Date, and receive the capital repayment in their bank account known to the Company.</p>
<div class="lb-trans"><p>直接在 Equiniti（前身为美国股票转让和信托公司（“AST”））持有 QIAGEN 股票的股东，计划根据上述合并比例自动合并其持股，并在生效日期生效，通过 Equiniti 持有的登记进行处理，并将资本偿还存入公司已知的银行账户。</p>
</div><p>Shareholders are advised to consult with their bank or broker with any questions on the reverse stock split and the capital repayment.</p>
<div class="lb-trans"><p>建议股东在有关反向股票拆分和资本偿还方面咨询其银行或经纪人。</p>
</div><p>Shareholders with questions about their tax status are advised to consult with their local tax advisor.</p>
<div class="lb-trans"><p>建议股东咨询当地税务顾问以了解其税务状况。</p>
</div><p><strong>About QIAGEN</strong></p>
<div class="lb-trans"><p><strong>关于 QIAGEN</strong></p>
</div><p>QIAGEN N.V., a Netherlands-based holding company, is a global leader in Sample to Insight solutions that enable customers to extract and analyze molecular information from biological samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis, while bioinformatics support the interpretation of complex data to deliver actionable insights. Automation solutions integrate these steps into streamlined, cost-effective workflows. QIAGEN serves more than 500,000 customers worldwide in the Life Sciences (academia, pharmaceutical R&amp;D and industrial applications such as forensics) and Molecular Diagnostics (clinical healthcare). As of September 30, 2025, QIAGEN employed approximately 5,700 people across over 35 locations. For more information, visit https://www.qiagen.com.</p>
<div class="lb-trans"><p>QIAGEN N.V.是一家总部位于荷兰的控股公司，是全球领先的样本到洞察解决方案提供商，使客户能够从包含生命基本构件的生物样本中提取和分析分子信息。我们的样本技术从血液、组织和其他材料中分离和处理 DNA、RNA 和蛋白质。检测技术为这些生物分子准备分析，而生物信息学支持复杂数据的解释，以提供可操作的洞察。自动化解决方案将这些步骤整合到简化、成本效益高的工作流程中。QIAGEN 在生命科学（学术界、制药研发和工业应用如法医）和分子诊断（临床医疗）领域为全球超过 500,000 名客户提供服务。截至 2025 年 9 月 30 日，QIAGEN 在 35 个以上的地点雇佣了约 5,700 名员工。有关更多信息，请访问 https://www.qiagen.com。</p>
</div><p><strong>Forward-Looking Statement</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p><em>Certain statements in this press release may constitute forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements, including those regarding QIAGEN’s products, development timelines, marketing and/or regulatory approvals, financial and operational outlook, growth strategies, capital allocation strategies, collaborations and operating results (such as expected net sales and adjusted diluted earnings), the CEO transition plan, the acquisition of Parse Biosciences, including the timing and expected benefits thereof, and the synthetic share repurchase, including the timing and expected befits thereof, are based on current expectations and assumptions. However, they involve uncertainties and risks. These risks include, but are not limited to: challenges in managing a successful CEO transition and successor search while providing operational continuity and continued advancement of company strategy; challenges in managing growth and international operations (including the effects of currency fluctuations, tariffs, tax laws, regulatory processes and logistical dependencies); variability in operating results and the commercial development of products for customers in the Life Sciences and clinical healthcare markets; changes in relationships with customers, suppliers or strategic partners; competition and rapid technological advancement; developments or changes in the securities markets and fluctuations in the trading volume and market price of QIAGEN’s shares and the successful implementation of the synthetic share repurchase; QIAGEN’s ability to successfully close, integrate and achieve the expected benefits of its acquisition of Parse Biosciences, including fluctuating demand for QIAGEN’s products due to factors such as economic conditions, customer budgets and funding cycles; obtaining and maintaining regulatory approvals for our products; difficulties in successfully adapting QIAGEN's products into integrated solutions and producing these products; and protecting product differentiation from competitors. Additional risks and uncertainties may arise from market acceptance of new products, integration of acquisitions, governmental actions, global or regional economic developments, natural disasters, political or public health crises, and other “force majeure” events. There is also no guarantee that anticipated benefits from restructuring programs and acquisitions will materialize as expected. For a more complete discussion of risks and uncertainties, please refer to the “Risk Factors” section in our most recent Annual Report on Form 20-F and other reports filed with or furnished to the U.S. Securities and Exchange Commission.</em></p>
<div class="lb-trans"><p>本新闻稿中的某些声明可能构成根据《1933 年美国证券法》第 27A 条和《1934 年美国证券交易法》第 21E 条的前瞻性声明。这些声明包括关于 QIAGEN 产品、开发时间表、市场和/或监管批准、财务和运营前景、增长战略、资本配置战略、合作关系和运营结果（如预期净销售额和调整后稀释每股收益）、首席执行官过渡计划、收购 Parse Biosciences 的时间及预期收益，以及合成股票回购的时间及预期收益，均基于当前的预期和假设。然而，这些声明涉及不确定性和风险。这些风险包括但不限于：在提供运营连续性和持续推进公司战略的同时，成功管理首席执行官过渡和继任者搜索的挑战；管理增长和国际运营的挑战（包括货币波动、关税、税法、监管流程和物流依赖的影响）；运营结果的变动以及为生命科学和临床医疗市场客户开发产品的商业化；与客户、供应商或战略合作伙伴关系的变化；竞争和快速的技术进步；证券市场的发展或变化以及 QIAGEN 股票的交易量和市场价格的波动，以及合成股票回购的成功实施；QIAGEN 成功完成、整合并实现收购 Parse Biosciences 的预期收益的能力，包括由于经济状况、客户预算和资金周期等因素导致的 QIAGEN 产品需求波动；获得和维持我们产品的监管批准；成功将 QIAGEN 的产品适应为综合解决方案并生产这些产品的困难；以及保护产品差异化以防止竞争对手的影响。市场对新产品的接受度、收购的整合、政府行为、全球或区域经济发展、自然灾害、政治或公共卫生危机以及其他 “不可抗力” 事件可能会带来额外的风险和不确定性。此外，重组计划和收购所预期的收益也没有保证会如预期那样实现。有关风险和不确定性的更完整讨论，请参阅我们最近的 20-F 表格年报和其他提交给或提供给美国证券交易委员会的报告中的 “风险因素” 部分。</p>
</div><p>Source: QIAGEN N.V.</p>
<div class="lb-trans"><p>来源：QIAGEN N.V.</p>
</div><p>Category: Corporate</p>
<div class="lb-trans"><p>类别：企业</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTgyMTcxNzJyMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20251218217172r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20251218217172/en/</p>
<div class="lb-trans"><p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251218217172/en/</p>
</div><p><strong>Contacts QIAGEN:</strong></p>
<div class="lb-trans"><p><strong>联系人 QIAGEN：</strong></p>
</div><p><strong>I</strong> <strong>nvestor Relations</strong></p>
<div class="lb-trans"><p><strong>投资者关系</strong></p>
</div><p>e-mail: ir@QIAGEN.com</p>
<div class="lb-trans"><p>电子邮件：ir@QIAGEN.com</p>
</div><p><strong>Public Relations</strong></p>
<div class="lb-trans"><p><strong>公共关系</strong></p>
</div><p>e-mail: pr@QIAGEN.com</p>
<div class="lb-trans"><p>电子邮件：pr@QIAGEN.com</p>
</div><p>Source: QIAGEN N.V.</p>
<div class="lb-trans"><p>来源：QIAGEN N.V.</p>
</div>

快而精医药宣布完成合成股票回购，金额最高约为 5 亿美元 | QGEN 股票新闻